{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-002284","form_type":"8-K","ticker":null,"cik":"0000910267","company_name":"TITAN PHARMACEUTICALS INC","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.764140+00:00","generated_at":"2026-05-24T01:21:21.309387+00:00","sec_items":["1.01","3.01","3.02","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Titan Pharmaceuticals raises $1M via Series B preferred, receives Nasdaq deficiency notice for equity shortfall","bullets":["Private placement of 100,000 Series B Preferred shares at $10 each for $1M aggregate; conversion price $3.00, convertible into ~333,333 common shares.","Nasdaq notified Titan on March 26, 2025, that stockholders' equity of $2.44M falls short of the $2.5M minimum requirement; company has 45 days to submit compliance plan.","Board appointed Gabriel Loh as independent director and Audit Committee member effective March 27, 2025.","Closing of the placement expected week of April 7, 2025; investor is Blue Harbour Asset Management L.L.C-FZ.","Registration rights granted to investor; securities issued under Regulation S without registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-002284","json":"https://secwatch.observer/filing/0001829126-25-002284.json","markdown":"https://secwatch.observer/filing/0001829126-25-002284.md","text":"https://secwatch.observer/filing/0001829126-25-002284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910267/000182912625002284/0001829126-25-002284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910267/000182912625002284/titanpharma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:21:21.309387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a371b97664b110a41be1b791546eba4a72ad559c","claim":"TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"March 26, 2025, the Company received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2024 (“2024 10-K”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2,500,000. In its 2024 10-K, the Company reported stockholders’ equity of $2,440,000, and, as a result, does not currently satisfy Nasdaq","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/910267/000182912625002284/0001829126-25-002284-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"84f40d6d70","claim":"Gabriel Loh was appointed as Independent Director at TITAN PHARMACEUTICALS INC.","evidence_excerpt":"On March 27, 2025, the board of directors of the Company (the “Board”) appointed Gabriel Loh as an independent director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/910267/000182912625002284/0001829126-25-002284-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}